8-KEarnings & ResultsRegulation FDExhibits & Filings

Merck & Co., Inc. 8-K Report, Financial Results (Oct 21, 2004)

Filed October 21, 2004For Securities:MRK

Summary

Schering-Plough Corporation (MRK) filed this 8-K on October 21, 2004, to report its financial results for the third quarter of 2004. The filing includes a press release detailing these results and supplemental financial data, both attached as exhibits. This report provides investors with an update on the company's operational and financial performance during the specified quarter. The company also included a significant disclosure regarding forward-looking statements and cautionary factors that could materially affect future results. Investors should pay close attention to these risks, which encompass competitive pressures, pricing challenges, regulatory uncertainties (including the impact of the Medicare Prescription Drug Act of 2003), product development risks, potential efficacy or safety concerns, patent disputes, and manufacturing compliance issues. The disclosure emphasizes that actual results may differ significantly from projections due to these factors.

Key Highlights

  • 1Schering-Plough reported its Third Quarter 2004 financial results via an 8-K filing.
  • 2The filing includes a press release (Exhibit 99.1) detailing the quarterly financial performance.
  • 3Supplemental financial data for the quarter is also provided as an exhibit (Exhibit 99.2).
  • 4The report contains extensive cautionary language regarding forward-looking statements.
  • 5Key risks highlighted include competitive pressures, pricing challenges, and regulatory impacts (e.g., Medicare Modernization Act).
  • 6Product development, manufacturing compliance, and patent disputes are identified as significant risk factors.
  • 7The company's major products (CLARITIN, CLARINEX, INTRON A, etc.) are noted as contributing materially to revenues, with associated risks.
  • 8The potential impact of new products like ZETIA and VYTORIN, and the launch of VYTORIN on ZETIA sales, is mentioned.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Schering-Plough's financial results for the third quarter of 2004. It includes the official press release announcing these results and additional supplemental financial data.

Schering-Plough disclosed a broad range of risks, including intense competition, increasing pricing pressure from payers, regulatory uncertainties (such as the Medicare Prescription Drug Act of 2003), challenges in product development, potential safety or efficacy concerns with marketed products, patent disputes, and issues related to manufacturing compliance. The company emphasizes that actual results could differ materially from forward-looking statements due to these factors.

Yes, the filing identifies major products such as CLARITIN, CLARINEX, INTRON A, PEG-INTRON, REBETOL Capsules, REMICADE, and NASONEX as accounting for a material portion of the company's 2003 revenues. It also mentions new products like ZETIA and VYTORIN and their potential impact on future revenues.

Schering-Plough explicitly states that it does not assume the obligation to update any forward-looking statements. Investors are cautioned that actual results may vary materially from projections, and there are no guarantees regarding future financial or operational performance.